secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001437749-25-010187
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics FY2024 net loss $24.5M; cash $20.9M at year-end, ~$25M at Q1 2025
--------------------------------------------------------------------------------

- Net loss $24.5M for 2024 vs $11.9M in 2023, driven by $9.7M intangible impairment and $2.5M SEC settlement.
- Cash and receivables $20.9M at Dec 31, 2024, and ~$25M at end of Q1 2025; expected to fund operations into 2027.
- R&D expenses decreased to $6.1M from $7.1M; G&A expenses $11.4M (including SEC accrual).
- Enrollment in Phase 2 ovarian cancer trial expected H1 2025; VA-funded SCLC combination trial enrollment Q2-Q3 2025.
- Authorized $5M share repurchase program; ATM program fully utilized and concluded.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000143774925010187/0001437749-25-010187-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000143774925010187/allr20250331_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-010187

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer